Page 258 - 2021_03-Haematologica-web

904
Letters to the Editor
AB
CD
EF
G
Figure 1. FAM122A is required for the growth and survival of acute myeloid leukemia cells. (A) The expression levels of FAM122A, FAM122B, and FAM122C mRNA were compared among hematopoietic stem and progenitor cells (HSPC), acute lymphoblastic leukemia and acute myeloid leukemia (AML) patients’ sam- ples in RNA-sequencing data from the Gene Expression Omnibus dataset (GSE48173). Each point presents the related gene expression of individual patients with horizontal lines indicating the median expression level in each group. *P<0.05 and ***P<0.001, compared with HSPC. ns: not statistically significant. (B) Kaplan-Meier plot showing the correlation between FAM122A expression and overall survival of AML patients from The Cancer Genome Atlas database. The patients were stratified into a high- and low-expression groups according to the median value of FAM122A expression. A log-rank test was performed to compare the survival curves of these two groups. P<0.01 was considered to indicate a statistically significant difference. (C) FAM122A protein was compared by western blot between three normal human peripheral blood mononuclear cell specimens and the indicated AML cell lines. (D) The effects of FAM122A knockdown in AML cells were confirmed by western blot (upper panels). The growth rates of FAM122A knockdown cells (designated shFAM122A#1 and shFAM122A#2) and control cells (shScramble) were monitored and analyzed by a cell counter (lower panels). (E) Re-expression of FAM122A with a shRNA-resistant plasmid carrying
haematologica | 2021; 106(3)